Predictive Oncology (NASDAQ: POAI), an artificial intelligence (“AI”) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through innovative data-driven products and services, this morning announced the broadcast of a NetworkNewsAudio (“NNA”) interview with Stuart Smith of NetworkNewsWire (“NNW”). Predictive Oncology CEO Dr. Carl Schwartz joined … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO Discusses Corporate, Scientific Milestones in NetworkNewsAudio Interview”
Predictive Oncology (NASDAQ: POAI) operates through five segments (Domestic, International, Clinical, CRO and DCHIP), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with … Continue reading “NetworkNewsAudio – Predictive Oncology (NASDAQ: POAI) Interview”
Predictive Oncology (NASDAQ: POAI), an artificial intelligence (“AI”) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through innovative data-driven products and services, on Friday announced its financial results for the quarter ended September 30, 2019 and provided a business update. Among the highlights, the company … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Reports Q3 Results, 58% Revenue Increase”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven, precision-medicine company, applies its smart tumor profiling and artificial intelligence (“AI”) platform to extensive genomic and biomarker patient data sets to predict and improve clinical outcomes for cancer patients. An article discussing the company reads, “While precision medicine, sometimes referred to as personalized medicine, is a relatively new term, … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Harnessing the Power of Artificial Intelligence to Improve Clinical Outcomes”
POAI subsidiary Helomics announce sequencing of ovarian tumor cases from UPMC Magee collaboration, a critical step in strategic Cancer Quest 2020 initiative Data key to value in $48-billion precision-medicine industry Industry leaders such as POAI realize critical value in patient-specific, data-driven models The field of drug development for cancer treatment involves costly and time-intensive research. … Continue reading “Predictive Oncology Inc.’s (NASDAQ: POAI) AI-Driven Predictive Models Better Inform Clinicians, Researchers; Changing Landscape of Cancer Treatment”
Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is utilizing the combined capabilities of AI with its extensive database of tumor data to assist clinicians in selecting the most effective drug treatments for cancer patients. An article discussing the company reads, “One disruptive aspect of POAI’s technology … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leverages Extensive Database, Artificial Intelligence to Identify Applicable Cancer Treatments”
Helomics chief technology officer speaks at inaugural UK 100,000 Genomes Project Conference The 100,000 Genomes Project is a UK-government project, sequenced whole genomes from National Health Service patients The depth of the project data is best in class, yielding useful benchmarks to help validate Helomics models Dr. Mark Collins, chief technology officer of Predictive Oncology … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary’s Officer Presents Initial Findings from Analysis of Landmark UK 100,000 Genomes Project”
Predictive Oncology is at forefront of growing trend of precision medicine The company applies smart tumor profiling, AI platform to extensive genomic and biomarker patient data sets POAI has large amounts of historical, standardized patient data from clinical testing that can be leveraged immediately The moment has come for Predictive Oncology Inc. (NASDAQ: POAI). A … Continue reading “Predictive Oncology Inc.’s (NASDAQ: POAI) Unique Assets, AI Capability Address Unmet Need in Growing Field of Precision Medicine”
Related Editorial Despite the enormous progress made in the war against cancers, ovarian cancer has proved to be a tenacious foe. Progress is being made, however, as AI predictive models are being used to better target deadly ovarian cancers. Ovarian cancer is difficult to treat and lethal, with survival rates much lower than other cancers … Continue reading “NetworkNewsAudio – Predictive Oncology (NASDAQ: POAI) Subsidiary Leverages Extensive Molecular Information Platform to Accelerate New Drug Development”
Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, this morning announced that its Helomics subsidiary has begun to sequence tumor cases from its collaboration with the UPMC Magee Women’s Hospital (http://nnw.fm/4uKXL). According to the update, the Helomics and UPMC Magee partnership focuses on analyzing the genomic and … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Achieves First Milestone in Cancer Quest 2020 Project”
